AR-1001 is under clinical development by AriBio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AR-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AR-1001 overview
AR-1001 is under development for the treatment of Alzheimer's disease, vascular dementia, Lewy body dementia, post traumatic stress disorder (PTSD), stroke and amyotrophic lateral sclerosis(ALS). The therapeutic candidate is formulated in tablet form and administered through oral route. The therapeutic candidate acts by targeting phosphodiesterase type 5 (PDE5). It was under development for the treatment of Parkinson's disease.
AriBio overview
AriBio Co Ltd is a biopharmaceutical business specialising in the development of novel medications to treat diseases including alzheimer’s, sepsis, and obesity. The company is headquartered in Seongnam-si, Gyeonggi-do, Republic of Korea (South Korea).
For a complete picture of AR-1001’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
